ALDX · Aldeyra Therapeutics, Inc.
$1.56
+0.00 (+0.00%)
At close · Aug 17
Market Cap
$94.11M
Shares
60.33M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.56
Open$1.55
Day$1.53–1.58
52W close$1.24–5.89
Avg vol 30d1.2M
Short int3.4M · 5.7% float · 3.1d
Short vol18%
Last earningsMay 4, 2023
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−52%
below
Price vs 50-day avg
−13%
below
RSI (14)
44
neutral
MACD trend
Positive
52-week position
7%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−70%
trailing
YTD return
−70%
this year
Relative strength
−82%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-16% holders QoQ · +19 funds added
Insider flow
Accumulating
Net +$418.5K over 90 days · 0% sells
Short interest
Falling
5.68% of float · ▼ -4.7% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
108 holders — mid 3-yr range
Squeeze score
56
elevated · 0–100
Fundamentals
EPS growth
+40%
Y/Y
Free cash flow
$-33.3M
Balance sheet
$54.8M
net cash
Quant / Vol
risk profile
Volatility
112%
annualized · 1-yr
Max drawdown
−79%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−52%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
44
Neutral
MACD trend
Positive
Bullish
52-week position
7%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-16% holders QoQ · +19 funds added
Insider flow
Accumulating
Net +$418.5K over 90 days · 0% sells
Short interest
Falling
5.68% of float · ▼ -4.7% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
108 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 7%
Range high $6
vs 200-day avg -52%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALDX
this stock
Aldeyra Therapeutics, Inc.
|
$94.11M | -69.9% | — | — | 5.7% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +19.3% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +13.7% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.4% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +17.5% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALDX | +3.3% | -8.2% | -70.1% | +1.3% | -69.9% |
| SPY | -0.1% | +4.1% | +12.4% | +3.4% | +13.3% |
| vs SPY | +3.4% | -12.4% | -82.5% | -2.1% | -83.2% |
Key facts
CIK
1341235
CUSIP
01438T106
13F (30d)
108 filings
99 filers
Visit website
Investor relations